This Tuesday, December 17, 2019, the incorporation of Dr. Maria Buti to the External Scientific Council of IDIVAL and the dismissal of Dr. Josep María Grinyo was approved in the Board of Trustees of IDIVAL.
Dr. Buti, is head of Hepatology and Internal Medicine at the Vall d'Hebron Hospital, principal investigator of the Hepatic Diseases group of the Vall d'Hebron Research Institute (VHIR) and researcher attached to the Center for Biomedical Research in Disease Network Hepatic and Digestive (CIBERehd). She is currently the Policy Counselor-elected of the EASL (leader of the Committee on Public Health and Political Relations of the European Association for the Study of the Liver) and has been president of the Spanish Association for the Study of the Liver (AEEH) during the years 2017- 2019.
Dr. Buti has published numerous scientific articles in leading journals, such as the New England Journal of Medicine, The Lancet, Hepatology, Gastroenterology and Journal of Hepatology and has been one of the most cited researchers according to the Clarivate Analytics list. In addition, Dr. Buti has led the studies on new drugs and major clinical trials of hepatitis B and D national and international in recent years and has collaborated as an expert in the Strategic Plan for the Approach of Hepatitis C in the System National Health (2015).
With the incorporation of Dr. Buti to the external scientific council of IDIVAL, the current composition of the External Council of IDIVAL appointed by the Board of Trustees of IDIVAL is as follows:
President:
Vowels:
Biomedical research and innovation are only possible thanks to everyone’s collaboration. This is how we move forward in improving the health of patients and the wider community